BE Study of Naftifine HCL
Public ClinicalTrials.gov record NCT02633813. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details. V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the end of week 2 + 2 days). V3- Follow up visit (at the end of week 4 + 2 days). V4 - Test of cure visit ( at the end of week 6 + 4 days).
Study identification
- NCT ID
- NCT02633813
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 693 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2015 (Type not available)
- Primary completion
- Nov 2015 (Actual)
- Completion
- Dec 2015 (Actual)
- Last update posted
- May 11, 2017
2015
United States locations
- U.S. sites
- 12
- U.S. states
- 3
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moore Clinical Research Inc | Brandon | Florida | 33511 | — |
| Savin Medical Group Research | Miami | Florida | 33014 | — |
| International Dermatology Research, Inc, | Miami | Florida | 33144 | — |
| FXM Research Corp | Miami | Florida | 33175 | — |
| FXM Research Miramar | Miramar | Florida | 33027 | — |
| South Tampa, MOORE Clinical Research, Inc. | Tampa | Florida | 33609 | — |
| North Tampa MOORE Clinical Research, Inc. | Tampa | Florida | 33618 | — |
| Medi Search | Saint Joseph | Missouri | 64506 | — |
| Bellaire Dermatology Associates | Bellaire | Texas | 77401 | — |
| Research Across America | Dallas | Texas | 75234 | — |
| Family Practise | Mesquite | Texas | 75149 | — |
| Research Across America | Plano | Texas | 75093 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02633813, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2017 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02633813 live on ClinicalTrials.gov.